HSDT - Helius Medical Technologies, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
10.10
+0.14 (+1.41%)
As of 10:19AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close9.96
Open9.96
Bid10.03 x 900
Ask10.20 x 900
Day's Range9.90 - 10.20
52 Week Range2.12 - 13.20
Volume37,697
Avg. Volume41,550
Market Cap236.17M
Beta (3Y Monthly)-0.35
PE Ratio (TTM)N/A
EPS (TTM)-1.27
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Helius Medical Technologies, Inc. Reports Third Quarter 2018 Financial Results

    NEWTOWN, Pa., Nov. 08, 2018 -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness,.

  • GlobeNewswire12 days ago

    Helius Medical Technologies to Present at the 12th Annual Canaccord Medical Technologies & Diagnostics Forum

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the 12th Annual Canaccord Medical Technologies & Diagnostics Forum at the Westin Grand Central Hotel in New York, New York. A live audio webcast of the conference presentation will be provided under the ‘Events’ section of the Helius Medical Technologies investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events. Helius Medical Technologies is a neurotech company focused on neurological wellness.

  • GlobeNewswire20 days ago

    Helius Medical Technologies, Inc. Announces Second Partnership to Implement Clinical Experience Programs with PoNS™ Treatment in the United States

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that its wholly owned subsidiary, NeuroHabilitation Corporation, has partnered with Northwell Health’s Feinstein Institute for Medical Research in Manhasset, NY. This partnership will enable Helius to implement its second Clinical Experience Program (CEP) for its Portable Neuromodulation Stimulator (PoNS™) -- an investigational medical device in the US currently under review for market clearance by the US Food & Drug Administration. PoNS is a licensed class II medical device in Canada.

  • GlobeNewswire22 days ago

    Helius Medical Technologies Receives Medical Device License Clearance from Health Canada for PoNS™ Device

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced its wholly owned subsidiary, NeuroHabilitation Corporation, received authorization from Health Canada to market its Portable Neuromodulation Stimulator (PoNS™), a class II medical device in Canada. The Health Canada Medical Device License certifies the PoNS Device meets all Canadian safety, effectiveness, and quality requirements. The Canadian Medical Device License approval was preceded by the Company’s achievement of ISO 13485 Certification, the international standard for medical device quality management systems.

  • GlobeNewswire26 days ago

    Helius Medical Technologies to Release Third Quarter 2018 Financial Results on November 8, 2018

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that third quarter 2018 financial results will be released after the market closes on Thursday, November 8. A live webcast of the call will also be provided on the Events section of the Company's investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events. The webcast will be archived on the Events section of the Company’s investor relations website.

  • GlobeNewswirelast month

    Helius Medical Technologies and HealthTech Connex Announce Alliance to Build Canadian Commercial Infrastructure

    HealthTech Connex Inc., a Canadian innovative healthcare company and Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius”), a neurotech company focused on neurological wellness, today announced that the Company has entered into an agreement with HealthTech Connex, Inc. (“HTCI”) to develop and manage neuroplasticity clinics in Canada. “The joint venture agreement to establish a new entity called Heuro Canada is an important step in establishing the commercial infrastructure for both the PoNS™ Treatment and the NeuroCatch™ Platform brain measurement in Canada,” said Kirk Fisher, CEO of HealthTech Connex.

  • GlobeNewswirelast month

    Helius Medical Technologies and HealthTech Connex Announce Alliance to Build Canadian Commercial Infrastructure

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that the Company has entered into an agreement with HealthTech Connex, Inc. (“HTC”) to develop and manage neuroplasticity clinics in Canada. "We are excited to announce this strategic alliance with HealthTech Connex and look forward to establishing our commercial infrastructure in Canada," said CEO Philippe Deschamps. “The agreement to establish Heuro Canada is an important step in establishing the commercial infrastructure for both the PoNS™ Treatment and the NeuroCatch™ Platform measurement in Canada,” said Kirk Fisher, CEO of HealthTech Connex.

  • GlobeNewswire2 months ago

    Helius Medical Technologies Submits Medical Device License Application to Health Canada for PoNS™ Device

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced its wholly owned subsidiary NeuroHabilitation Corporation, submitted an application for a Class II Medical Device License to Health Canada to market its Portable Neuromodulation Stimulator (PoNS™), an investigational medical device. “The Company is pleased to submit our Class II Medical Device License application to market our PoNS Device as an adjunct to physical therapy for the treatment of chronic balance disorder in patients with mild- to moderate-traumatic brain injury,” said Philippe Deschamps, Helius’ President, CEO and Chairman.

  • GlobeNewswire2 months ago

    Helius Medical Technologies to Participate in Three Upcoming Conferences in October

    Live audio webcasts of the MicroCap Conference and Ladenburg Thalmann 2018 Healthcare Conference presentations at the venues will be provided under the ‘Events’ section of the Helius Medical Technologies investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events. Archives of the webcasts will be available for replay following the conferences.

  • Who Are The Top Investors In Helius Medical Technologies Inc (NASDAQ:HSDT)?
    Simply Wall St.2 months ago

    Who Are The Top Investors In Helius Medical Technologies Inc (NASDAQ:HSDT)?

    Every investor in Helius Medical Technologies Inc (NASDAQ:HSDT) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual toRead More...

  • GlobeNewswire2 months ago

    Helius Announces First Partnership to Implement Clinical Experience Programs With the Investigational PoNS™ Therapy in the United States

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that it has partnered with The Ohio State University Wexner Medical Center, a leading U.S. neurorehabilitation center located in Columbus, OH to establish the Company’s first Clinical Experience Program for the Company’s Portable Neuromodulation Stimulator (PoNS™), an investigational medical device.

  • GlobeNewswire2 months ago

    Helius Medical Technologies to Participate in the 20th Annual Global Investment Conference Sponsored by Rodman & Renshaw and H.C. Wainwright & Co.

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced it will be featured as a presenting company at the 20th Annual Global Investment Conference sponsored by Rodman & Renshaw and H.C. Wainwright & Co. at the St. Regis New York in New York, New York. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first product in development is the Portable Neuromodulation Stimulator (PoNS).  For more information, visit www.heliusmedical.com.

  • GlobeNewswire2 months ago

    Helius Medical Technologies Submits Request for FDA 510(k) Clearance of the PoNS™ Device

    Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that the Company has submitted a request to the U.S. Food and Drug Administration (“FDA”) for de novo classification and 510(k) clearance of the Portable Neuromodulation Stimulator (PoNS™) device. “Helius is excited to announce the submission of our request for de novo classification and 501(k) clearance of the PoNS device for the treatment of chronic balance deficit due to mild- to moderate-traumatic brain injury,” said Philippe Deschamps, Helius’ President, CEO and Chairman. The Company’s request for de novo classification and 510(k) clearance is supported by clinical data from two double-blind, randomized, controlled trials demonstrating the PoNS device’s safety and efficacy, with combined enrollment of 163 patients.

  • Is Helius Medical Technologies Inc (NASDAQ:HSDT) Overpaying Its CEO?
    Simply Wall St.7 months ago

    Is Helius Medical Technologies Inc (NASDAQ:HSDT) Overpaying Its CEO?

    Phil Deschamps took the helm as Helius Medical Technologies Inc’s (NASDAQ:HSDT) CEO and grew market cap to US$206.96M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucialRead More...